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Abstract
Objective Many adults with congenital heart disease (CHD)
are affected lifelong by cardiac events, particularly arrhyth-
mias and heart failure. Despite the care provided, the car-
diac event rate remains high. Mobile health (mHealth)
brings opportunities to enhance daily monitoring and hence
timely response in an attempt to improve outcome. How-
ever, it is not known if adults with CHD are currently using
mHealth and what type of mHealth they may need in the
near future.
Methods Consecutive adult patients with CHD who visited
the outpatient clinic at the Academic Medical Center in
Amsterdam were asked to fill out questionnaires. Exclusion
criteria for this study were mental impairment or inability
to read and write Dutch.
Results All 118 patients participated (median age 40 (range
18–78) years, 40 % male, 49 % symptomatic) and 92 %
owned a smartphone. Whereas only a small minority (14 %)
of patients used mHealth, the large majority (75 %) were
willing to start. Most patients wanted to use mHealth in
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order to receive more information on physical health, and
advice on progression of symptoms or signs of deteriora-
tion. Analyses on age, gender and complexity of defect
showed significantly less current smartphone usage at older
age, but no difference in interest or preferences in type of
mHealth application for the near future.
Conclusion The relatively young adult CHD population
only rarely uses mHealth, but the majority are motivated to
start using mHealth. New mHealth initiatives are required
in these patients with a chronic condition who need lifelong
surveillance in order to reveal if a reduction in morbidity
and mortality and improvement in quality of life can be
achieved.
Keywords Congenital heart disease · GUCH · Mobile
health · mHealth · eHealth · Lifestyle · Quality of life ·
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Introduction
Over past decades the life expectancy of children with con-
genital heart disease (CHD) has increased dramatically,
mainly due to the successes of cardiac surgery [1]. At
present, nearly all children with CHD can be operated on
at young age and more than 95 % reach adulthood. How-
ever, many adults with CHD are affected lifelong by cardiac
symptoms, reduced quality of life, and cardiac events [2–6].
These events often merit medical therapy, percutaneous in-
terventions, and open-heart surgery to improve survival and
quality of life [1, 6–8]. Consequently, adults with CHD
are frequently admitted to hospital, entailing high health-
related and non-health-related costs to the affected individ-
uals, employers, and to society at large.
648 Neth Heart J (2016) 24:647–652
Fig. 1 The questionnaire with
15 mobile health-related ques-
tions
Do you have a smartphone (e.g. iPhone / Samsung / 
Windows Phone)?
No O----------------------O      Yes
Do you use a medical applicaon ("app") to improve your 
health?
No O----------------------O      Yes
Would you like to receive informaon about your 
congenital heart disease on your smartphone?
1       O-----O-----O-----O-----O       5
Not at all Absolutely
Would you like to receive informaon about a healthy 
lifestyle on your smartphone?
1       O-----O-----O-----O-----O       5
Not at all Absolutely
Are you willing to ﬁll in vitals / measurements on your 
smartphone?
1       O-----O-----O-----O-----O       5
Not at all Absolutely
Are you willing to ﬁll in symptoms on your smartphone? 1       O-----O-----O-----O-----O       5
Not at all Absolutely
Are you willing to ﬁll in your quality of life on your 
smartphone?
1       O-----O-----O-----O-----O       5
Not at all Absolutely
Are you willing to ﬁll in your lifestyle on your 
smartphone?
1       O-----O-----O-----O-----O       5
Not at all Absolutely
Are you willing to ﬁll in your medicaon on your 
smartphone?
1       O-----O-----O-----O-----O    5
Not at all Absolutely
Would you like your cardiologist to advise you on your 
smartphone in the event of aberrant vitals / 
measurements?
1       O-----O-----O-----O-----O       5
Not at all Absolutely
Would you like your cardiologist  to advise you on your 
smartphone if  you have symptoms?
1       O-----O-----O-----O-----O       5
Not at all Absolutely
Would you like to receive smulang messages to 
improve your lifestyle?
1       O-----O-----O-----O-----O       5
Not at all Absolutely
Would you like to receive reminders to take your 
medicaon?
1       O-----O-----O-----O-----O       5
Not at all Absolutely
Would you like to help with the development of an app? No O----------------------O      Yes
Would you use a specially developed app to improve your 
health and maintain beer contact with your 
cardiologist?
No O----------------------O      Yes
Care of adults with CHD is mainly organised at an outpa-
tient clinic. Patients with CHD are usually under lifelong
outpatient surveillance. These outpatient visits are brief
evaluations of clinical status, patient education and treat-
ment strategies and include an ECG, cardiac imaging and
short-term monitoring; such as 24- or 48-hour blood pres-
sure measurements. These outpatient evaluations are only
momentary snapshots. The frequency of outpatient visits
ranges from a few times a year to once every five years [2].
Continuous monitoring is rare. Consequently, patients may
develop symptoms or signs of deterioration between visits,
which could therefore be missed.
Mobile health (mHealth) is the provision of medical care
facilitated by mobile technologies capable of delivering
health information, monitoring clinical signs and enabling
direct care and patient education [9]. There are many po-
tential uses of mHealth, such as E-support, E-care, tele-
monitoring, tele-treatment, teleconsultation and tele-diag-
nosis [10, 11]; mHealth brings opportunities to stimulate
a healthy life style, to remind patients on medication use,
and to enhance monitoring in an attempt to improve out-
come. However, it is not known if adults with CHD are
currently using mHealth or what type of mHealth they will
need in the near future.
Methods
Study design and population
Consecutive adult patients with CHD who visited the outpa-
tient clinic at the Academic Medical Center in Amsterdam
were asked to fill out a questionnaire directly at the out-
patient visit. Exclusion criteria for this study were mental
impairment and the inability to speak or write Dutch. This
is decided by the treating physician. This study was ex-
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empted from approval of the Medical Ethics Committee
of the Academic Medical Center in Amsterdam (reference
number W16_057), because it was not burdensome for the
patient. The Ethics Committee gave us permission to link
the questionnaire data to electronic medical records.
Data collection
Data were collected using an mHealth questionnaire, in-
cluding 15 mobile-health-related questions (Fig. 1). The
questionnaire incorporated four general mobile health ques-
tions (binary scale) and eleven questions on patient moni-
toring preferences (Likert scale). These questions on patient
preferences included two questions related to information
provision, four questions related to willingness of patients
to enter data, and four questions related to therapy. In order
to make the term mHealth clear to patients and to minimise
wide interpretability, the mHealth questionnaire was con-
centrated on a smartphone. The questionnaire was designed
by three authors (MJS, BJM and BJB) and has not been
validated. Clinical characteristics were obtained from elec-
tronic medical records. Medical records were used to iden-
tify cardiac surgery, pacemaker and ICD implantations, use
of diuretics and anti-arrhythmic drugs. The type of CHD
was categorised as a simple, moderate or complex defect
in accordance with the Bethesda conference [12]. Patient
functional status was operationalised in accordance with the
New York Heart Association (NYHA) classification.
Statistics
For statistical analysis SPSS 23 (SPSS Inc., Chicago, Illi-
nois) was used. Descriptive statistics for nominal data
were presented in percentages. Continuous variables were
expressed as mean ± standard deviation when normally
distributed, and median if otherwise. Categorical vari-
ables were compared with the chi-square test. Independent
t-tests for quantitative data were applied to detect differ-
ences between groups. NYHA II, NYHA III and NYHA IV
were lumped together in the category symptomatic patients.
A p 0.05 was considered statistically significant.
Results
Characteristics of participants
All 118 adults with CHD participated. Median age was 40
(range 18–78) years, 40 % of the patients were male, and
49 % were symptomatic. Table 1 summarises patient char-
acteristics. Amongst participants, 23 % had a simple, 52 %
a moderate and 25 % a complex CHD. Most patients had
undergone cardiac surgery and antiarrhythmic drugs were
prescribed more frequently than diuretics. In total 92 %
of all adults with CHD owned a smartphone. The oldest
quartile of patients (median age 54 years) used a smart-
phone significantly less often than the youngest quartile of
patients (median age 26 years) (Table 2).
Willingness of adults with congenital heart disease to
use mHealth
Whereas a small minority (14 %) of patients with CHD al-
ready used mHealth, the majority (75 %) were willing to
start using mHealth (Fig. 2). There were no differences be-
tween the oldest and youngest patient categories in current
use of mHealth, willingness to start using mHealth and will-
ingness to help in development of new mHealth initiatives
(Table 2).
Table 1 Clinical characteristics of participating adults with
congenital heart disease
Study group
N = 118
Median age, years (range) 40 (18–78)
Male % 40
Own a smartphone, % 92
Disease complexity
Simple % 23
Moderate % 52
Complex, % 25
New York Heart Association
Class I % 51
Class ≥ II % 49
Event history
Cardiac surgery % 76
Pacemaker/ICD implantation % 6
Medication
Diuretics % 10
Anti-arrhythmic % 30
Table 2 Characteristics of younger versus older participating adults
with congenital heart disease
Study group Study
group
p
Youngest
quartile
Oldest
quartile
N = 30 N = 30
Use of a smartphone 29 24 0.026
Use of a mobile health
application
2 3 0.668
Ready to use a mobile
health application
21 22 0.781
Ready to help in develop-
ment of application
15 15 0.436
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Fig. 2 Current mobile health use and willingness to start using mobile health in 118 adults with congenital heart disease
Fig. 3 Preferences on parameters to monitor with mobile health in
adults with congenital heart disease
Patient preferences on parameters to monitor with
mHealth
The majority of adults with CHD stated willingness to use
mHealth to receive information about their disease (71 %),
and about a healthy lifestyle (69 %), (Fig. 3). The major-
ity of adults with CHD also stated their willingness to use
mHealth to provide information on symptoms (73 %), vitals
(75 %) and quality of life (69 %). Therapy, as expressed by
advice on worsening symptoms and abnormal vitals, was
highly valued (median both 4 out of 5, Fig. 3). The major-
ity of patients wanted to receive advice from their treating
cardiologist in the event of aberrant parameters and progres-
sion of symptoms, and they also wanted to receive stimulat-
ing messages. Medication reminders were not considered
useful. No differences in preferences for any particular type
of mHealth were found between male and female patients,
symptomatic and asymptomatic patients and patients with
simple and complex disease (Table 3).
Discussion
To our knowledge, this is the first report on the readiness of
adults with CHD to use mHealth for their condition. The
majority of patients with CHD are willing to start using
mHealth, but only a small proportion actually uses it cur-
rently. All subgroups studied were interested in mHealth,
implying that mHealth might be a widely applicable tool in
the follow-up of adult patients with CHD.
The adult CHD population is a highly attractive group in
which to initiate mHealth initiatives due to their relatively
young age, affinity with mobile devices, chronic condition
necessitating lifelong surveillance, and the general need to
reduce the burden of disease. mHealth has the potential to
empower patients and support them in their daily struggles.
The additional monitoring of clinical parameters (e. g. heart
rate, blood pressure, weight, etc.) might enable physicians
and specialised nurses to improve the early recognition of
clinical deterioration and to deliver sophisticated patient-
tailored care remotely, e. g. titration of diuretics and antiar-
rhythmic agents. Lifelong surveillance gives clinicians the
opportunity to support patients to continue using mHealth.
Consequently, mHealth opens opportunities to maintain the
motivation to achieve a sustainable improvement. For in-
stance, the short-term beneficial effects of training on exer-
cise capacity in adult patients with CHD have already been
demonstrated [13], but without long-term durability when
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Table 3 Subgroup analysis on preferences in mHealth in adults with congenital heart disease
Male Female p Symptomatic Not symp-
tomatic
p Simple
defect
Complex
defect
p
More info on disease 3.59 3.48 ns 3.51 3.5 ns 3.58 3.63 ns
More info on lifestyle 3.59 3.48 ns 3.36 3.62 ns 3.83 3.37 ns
Collect vitals 3.67 3.66 ns 3.64 3.67 ns 3.83 3.93 ns
Collect symptoms 3.67 3.52 ns 3.58 3.53 ns 3.92 3.74 ns
Collect quality of life 3.43 3.41 ns 3.29 3.47 ns 3.71 3.52 ns
Collect lifestyle 3.38 3.46 ns 3.4 3.39 ns 3.71 3.58 ns
Collect medication use 3.57 3.72 ns 3.64 3.65 ns 4,00 3.63 ns
Advice on abnormal
vitals
3.74 3.83 ns 3.69 3.9 ns 4.08 4.22 ns
Advice on worsening
symptoms
3.52 3.83 ns 3.7 3.71 ns 3.92 4.08 ns
Stimulating messages 3.07 3.15 ns 3.02 3.16 ns 3.58 3.15 ns
Medication reminders 2.83 2.39 ns 2.29 2.74 ns 2.88 2.44 ns
ns not significant
the training period is over [14]. Conceivably, mHealth in-
terventions could overcome this limitation by continuous
support and motivational tools.
Overall, studies on the efficacy of mHealth initiatives
in cardiology are rare. The results of mHealth studies in
heart failure patients, carried out in patients with acquired
heart disease, are conflicting [15–17]. Some telemonitoring
studies using implantable cardioverter defibrillators have
demonstrated that telemonitoring enhances life expectancy
and reduces the number of related clinical events in heart
failure patients [15]. However, a study using a phone-
based telemonitoring system found no differences in all-
cause mortality, hospital readmission rates, or readmissions
in these patients [17]. Recently, the American Heart As-
sociation (AHA) reviewed a total of 13 mHealth studies
on prevention of cardiovascular disease and concluded an
absence of efficacy data and data on sustainability of en-
gagement by the individual and thus sustainability of the
treatment effect, an issue that is extremely important in
managing chronic conditions [18]. The European Society
of Cardiology is facilitating an action plan pertaining to
mHealth issues [9]. This action plan aims at a wider imple-
mentation of electronic technology, education and training,
in order to play an active role in discussions and to set qual-
ity standards. Although adults with CHD are a large group
who are particularly suited to mHealth, neither of the posi-
tion papers comments on this specific patient population.
Both patients and clinicians need to be committed to
mHealth interventions in order to achieve long-term impact.
In a recent mHealth trial on diet and exercise behaviour in
healthy volunteers with an increased risk of atherosclerosis,
the dropout rate was as high as 20 % [19]. Therefore, it is
important to seek the right balance between time-consum-
ing data collection and dropout. Adults with CHD could
benefit from increased adherence because of the necessity
for lifelong surveillance [2].
Four other important points are safety, privacy, reim-
bursement and implementation. At this stage, there is a lack
of legal clarity and a lack of transparency regarding the
utilisation of the data collected [9]. Data encryption and
secured connections are needed to prevent leaks of private
data [9]. Before implementation, clear communications on
response time are required to prevent patients waiting for
a message from a treating physician. For example, outside
office hours the telephone number of the cardiac emergency
care unit could be shown if immediate attention is neces-
sary, but there would also be the facility to use mHealth to
contact a physician with a reasonable response time of 24 h,
for instance. There is also significant physician hesitation
about implementing mHealth. Patients could potentially
overload physicians and nurses with additional work and
medical professionals have concerns about the quality of
the data generated by mHealth devices [11, 20]. Addition-
ally, many physicians are not reimbursed for mHealth. At
this stage mHealth is only reimbursed in a limited number
of cases, and reimbursement is commonly not in proportion
to the time required [11].
Our study has several limitations. At first, the mHealth
questionnaire was confined to a smartphone in order to min-
imise vagueness about the term mHealth. However, there
are many other forms of mHealth. Secondly, the question-
naire was designed by three authors and was not validated.
Conclusion
The adult CHD population rarely uses mHealth, but the
majority is motivated to start using mHealth for their con-
dition. These patients seem particularly attractive for new
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mHealth initiatives because of their young age, affinity with
mobile devices, chronic condition with the necessity of life-
long surveillance, and the general need to reduce the bur-
den of disease. New mHealth initiatives are needed to re-
veal whether a reduction in morbidity and mortality and
improvement in quality of life can be achieved with early
event recognition and intervention.
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